Vellenga E - Search Results

1

Multidrug resistance protein MRP1, glutathione, and related enzymes. Their importance in acute myeloid leukemia.

van der Kolk DM, Vellenga E, Müller M, de Vries EG. van der Kolk DM, et al. Among authors: vellenga e. Adv Exp Med Biol. 1999;457:187-98. doi: 10.1007/978-1-4615-4811-9_20. Adv Exp Med Biol. 1999. PMID: 10500793 Review.

2

The combined effects of IL-3 and PSC 833 on daunorubicin- and mitoxantrone cytotoxicity in two growth factor-dependent leukemic cell lines.

Asschert J, de Vries E, van der Kolk D, Müller M, Vellenga E. Asschert J, et al. Among authors: vellenga e. Leukemia. 1997 May;11(5):680-6. doi: 10.1038/sj.leu.2400639. Leukemia. 1997. PMID: 9180292

3

Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells.

van der Kolk DM, de Vries EG, Koning JA, van den Berg E, Müller M, Vellenga E. van der Kolk DM, et al. Among authors: vellenga e. Clin Cancer Res. 1998 Jul;4(7):1727-36. Clin Cancer Res. 1998. PMID: 9676848

4

Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity.

van Der Kolk DM, Vellenga E, van Der Veen AY, Noordhoek L, Timmer-Bosscha H, Ossenkoppele GJ, Raymakers RA, Müller M, van Den Berg E, de Vries EG. van Der Kolk DM, et al. Among authors: vellenga e. Blood. 2000 Jun 1;95(11):3514-9. Blood. 2000. PMID: 10828037 Free article.

5

P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.

van der Kolk DM, de Vries EG, van Putten WJ, Verdonck LF, Ossenkoppele GJ, Verhoef GE, Vellenga E. van der Kolk DM, et al. Among authors: vellenga e. Clin Cancer Res. 2000 Aug;6(8):3205-14. Clin Cancer Res. 2000. PMID: 10955805

6

Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia.

van der Kolk DM, de Vries EG, Noordhoek L, van den Berg E, van der Pol MA, Müller M, Vellenga E. van der Kolk DM, et al. Among authors: vellenga e. Leukemia. 2001 Oct;15(10):1544-53. doi: 10.1038/sj.leu.2402236. Leukemia. 2001. PMID: 11587212

7

VP-16-mediated cytotoxicity is modulated by interleukin-3 in a growth factor-dependent leukemic cell line.

Vellenga E, Asschert L, Withoff S, van der Kolk D, de Vries EG. Vellenga E, et al. Leukemia. 1994 Dec;8(12):2060-4. Leukemia. 1994. PMID: 7807995

8

Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.

van der Graaf WT, de Vries EG, Timmer-Bosscha H, Meersma GJ, Mesander G, Vellenga E, Mulder NH. van der Graaf WT, et al. Among authors: vellenga e. Cancer Res. 1994 Oct 15;54(20):5368-73. Cancer Res. 1994. PMID: 7923167

9

Mutual interactions between p53 and growth factors in cancer.

Asschert JG, Vellenga E, De Jong S, de Vries EG. Asschert JG, et al. Among authors: vellenga e. Anticancer Res. 1998 May-Jun;18(3A):1713-25. Anticancer Res. 1998. PMID: 9673395 Review.

10

Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: involvement of AP-1.

Asschert JG, De Vries EG, De Jong S, Withoff S, Vellenga E. Asschert JG, et al. Among authors: vellenga e. Int J Cancer. 1999 Apr 12;81(2):236-42. doi: 10.1002/(sici)1097-0215(19990412)81:2<236::aid-ijc12>3.0.co;2-r. Int J Cancer. 1999. PMID: 10188725

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

498 results

Search Page

Filters